{"id":9733,"date":"2021-05-11T15:55:22","date_gmt":"2021-05-11T22:55:22","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9733"},"modified":"2021-05-12T15:56:06","modified_gmt":"2021-05-12T22:56:06","slug":"prevalence-of-antibody-positivity-to-sars-cov-2-following-the-first-peak-of-infection-in-england-serial-cross-sectional-studies-of-365000-adults","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/11\/prevalence-of-antibody-positivity-to-sars-cov-2-following-the-first-peak-of-infection-in-england-serial-cross-sectional-studies-of-365000-adults\/","title":{"rendered":"Prevalence of Antibody Positivity to SARS-CoV-2 Following the First Peak of Infection in England: Serial Cross-Sectional Studies of 365,000 Adults"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The prevalence of anti-spike SARS-CoV-2 antibodies in England was 5% by the end of September 2020 (prior to the onset of vaccination campaigns), according to three cross-sectional national surveys with non-overlapping random samples undertaken between late June to September (n&gt;365,000). The prevalence of detectable antibodies over the three rounds was 6%, 5%, and 4%. The highest prevalence and smallest overall decline (15% decline) in antibody positivity was in the youngest age group (18-24 years), while lowest prevalence and largest decline (39% decline) was observed in the oldest group (&gt;74 years). Prevalence declined by 64% among those who did not report prior SARS-CoV-2 infection and by 22% among those with PCR-confirmed infection.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Ward et al. (May 2, 2021). Prevalence of Antibody Positivity to SARS-CoV-2 Following the First Peak of Infection in England: Serial Cross-Sectional Studies of 365,000 Adults. The Lancet Regional Health &#8211; Europe. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100098\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.lanepe.2021.100098<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The prevalence of anti-spike SARS-CoV-2 antibodies in England was 5% by the end of September 2020 (prior to the onset of vaccination campaigns), according to three cross-sectional national surveys with non-overlapping random samples undertaken between late June to September (n&gt;365,000). The prevalence of detectable antibodies over the three rounds was 6%, 5%, and 4%. The&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/11\/prevalence-of-antibody-positivity-to-sars-cov-2-following-the-first-peak-of-infection-in-england-serial-cross-sectional-studies-of-365000-adults\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[67,29],"topic":[16],"class_list":["post-9733","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-antibodies","tag-public-health","topic-public-health-policy-and-practice"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9733"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9733\/revisions"}],"predecessor-version":[{"id":9734,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9733\/revisions\/9734"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9733"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}